Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Balazs Halmos

Showing results (211-220 of 221) with videos related to

Pageof 23
Sort By:
JTO Clinical and Research Reports|May 27, 2022
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT AnalysisChristine M Bestvina, Jennifer G Whisenant, Valter Torri, et al.
Nature Genetics|July 4, 2012
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerZhenfeng Zhang, Jae Cheol Lee, Luping Lin, et al.
Science Translational Medicine|August 5, 2016
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expressionKol Jia Yong, Daniela S Basseres, Robert S Welner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Thrombosis and Haemostasis : JTH|July 14, 2021
The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19Ang Li, Nicole M Kuderer, Chih-Yuan Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Cancer Discovery|July 24, 2020
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyDonna R Rivera, Solange Peters, Orestis A Panagiotou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2022
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT RegistryJennifer G Whisenant, Javier Baena, Alessio Cortellini, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Pageof 23

Showing results (211-220 of 221) with videos related to

Sort By:
Pageof 23
JTO Clinical and Research Reports|May 27, 2022
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT AnalysisChristine M Bestvina, Jennifer G Whisenant, Valter Torri, et al.
Nature Genetics|July 4, 2012
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancerZhenfeng Zhang, Jae Cheol Lee, Luping Lin, et al.
Science Translational Medicine|August 5, 2016
Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expressionKol Jia Yong, Daniela S Basseres, Robert S Welner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0Sonam Puri, Natasha B Leighl, Nofisat Ismaila, et al.
Journal of Thrombosis and Haemostasis : JTH|July 14, 2021
The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19Ang Li, Nicole M Kuderer, Chih-Yuan Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 3, 2026
Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.0Joshua E Reuss, Lyudmila Bazhenova, Nofisat Ismaila, et al.
Cancer Discovery|April 2, 2024
Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsFederica Pecci, Seshiru Nakazawa, Biagio Ricciuti, et al.
Cancer Discovery|July 24, 2020
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort StudyDonna R Rivera, Solange Peters, Orestis A Panagiotou, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 5, 2022
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT RegistryJennifer G Whisenant, Javier Baena, Alessio Cortellini, et al.
Lung Cancer (Amsterdam, Netherlands)|October 18, 2025
Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexityAlessio Cortellini, Edoardo Garbo, Giulia La Cava, et al.
Pageof 23